VIJAYA2023-04-012023-06-30 VIJAYA2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member VIJAYA2023-06-30 VIJAYA2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543350 VIJAYA NOTLISTED Vijaya Diagnostic Centre Limited Equity 2023-04-01 2024-03-31 2023-08-09 2023-07-31 INR Lakhs First quarter 12:00:00 14:15:00 2023-08-09 2023-08-09 Not applicable Single segment Diagnostic Services 2023-04-01 2023-06-30 Unaudited Consolidated 1210496000.00 57067000.00 1267563000.00 142876000.00 0.00 0.00 208493000.00 58825000.00 124700000.00 377943000.00 912837000.00 354726000.00 0.00 354726000.00 71050000.00 19830000.00 90880000.00 0.00 263846000.00 0.00 0.00 0.00 0.00 263846000.00 485000.00 264331000.00 262037000.00 1809000.00 262522000.00 1809000.00 102117000.00 1 2.57 2.56 0.00 0.00 2.57 2.56 1. The above consolidated financial results of Vijaya Diagnostic Centre Limited ( the Company ) and its subsidiaries (the Company and its subsidiaries together referred to as the Group ) have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ( Ind AS ) prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 09 August 2023. The statutory auditors have carried out limited review of the above results for the quarter ended 30 June 2023. An unmodified report has been issued by them thereon. 3. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 Operating Segments . 4. The consolidated figures for the quarter ended 31 March 2023 is the balancing figure between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter ended 31 December 2022, which were subject to limited review. 5. The Group has charged depreciation on Property, Plant and Equipment based on Written Down Value (“WDV ) method upto 31 December 2022. With effect from 01 January 2023, the Company has changed its method of depreciation from WDV to SLM (Straight Line Method) based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets.Accordingly, the depreciation expense is lower and profit before tax is higher by Rs. 790.92 lakhs for the quarter ended 30 June 2023 and by Rs. 904.34 lakhs for the quarter and year ended 31 March 2023. There is no impact on account of such change to the depreciation provided upto 31 December 2022 under WDV method. 6. During the quarter ended 30 June 2023 and year ended 31 March 2023, the Company has issued 46,118 and 105,249 equity shares of face value of Re. 1 each respectively on exercise of employee stock options. 7. During the quarter ended 30 June 2023, the Company has granted 251,291 employee stock options to eligible employees pursuant to the 'Employee Stock Option Plan 2018' as approved by the Nomination and Remuneration Committee of the Board of Directors at their meeting held on 29 May 2023. 8. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com 9. Corresponding previous period figures have been regrouped / reclassified wherever necessary. Other expenses 377943000.00 Remeasurement of defined benefit obligationsn 648000.00 648000.00 163000.00 0.00